DeepMed Research

Centro Nacional de Investigaciones Oncologicas CARLOS III

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Phase 2

Completed

Conditions: Adenocarcinoma of Colon
Adenocarcinoma of Rectum
Metastatic Disease

Interventions: Drug: arm B chemotherapy
Drug: Arm A chemotherapy

First Posted Date: 2012-10-11

Last Posted Date: 2015-10-09

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 29

Registration Number: NCT01703910

Locations: 🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
Hospital Madrid Norte Sanchinarro, Madrid, Spain

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Dovitinib + Paclitaxel
Drug: Dovitinib

First Posted Date: 2012-03-08

Last Posted Date: 2020-04-17

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 13

Registration Number: NCT01548924

Locations: 🇪🇸
Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
MD Anderson Cancer Centre, Madrid, Spain

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: BIBF + Paclitaxel
Drug: Paclitaxel

First Posted Date: 2011-12-02

Last Posted Date: 2020-01-27

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 140

Registration Number: NCT01484080

Locations: 🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
MD Anderson Cancer Centre Madrid, Madrid, Spain
🇪🇸
Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Phase 2

Completed

Conditions: Advanced Pancreatic Carcinoma

Interventions: Drug: gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.
Drug: Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI

First Posted Date: 2011-10-18

Last Posted Date: 2015-10-09

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 31

Registration Number: NCT01454180

Locations: 🇪🇸
Hospital Universitario Madrid Sanchinarro, Madrid, Spain
🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy